

Esophageal Cancer

Effective Date: October 2025



Background

There are two common distinct histologies of esophageal cancer. Chronic gastroesophageal reflux predisposes to Barrett's metaplasia and the development of adenocarcinoma¹. Typically, it develops within the distal esophagus; in North America, it is now more prevalent than the other histology, squamous cell carcinoma². The recognized risk factors for squamous cell carcinoma include tobacco and alcohol exposure³.

Guideline Questions

- What are the recommendations for the diagnostic workup of adult patients with esophageal cancer?
- What are the recommendations for treatment of adult patients with potentially curable esophageal cancer?
- What are the recommendations for management of adult patients with incurable esophageal cancer?

Search Strategy

This guideline was developed to promote evidence-based practice in Alberta. A formal literature search was conducted for the 2019 version of the guideline, and an informal literature search was used for the 2025 updated version of the guideline.

Target Population

The recommendations outlined in this guideline apply to adults over the age of 18 years with esophageal cancer, including both squamous cell and adenocarcinoma. Different principles may apply to pediatric patients.

Recommendations

Recommended Diagnostic Work-Up

- Esophagogastroduodenoscopy with biopsy establishes the tumour's location (distance from incisors) and histology.
- An augmented CT scan of the thorax, abdomen and pelvis also helps to establish the tumour's location, depth of penetration into the esophageal wall, invasion into adjacent structures, and involvement of regional and non-regional lymph nodes. Metastatic disease confers an incurable situation for which only palliative maneuvers would be appropriate.
- Blood work identifies any end-organ dysfunction that may preclude the safe administration of chemotherapy.
- if no metastatic disease is seen on the baseline CT, F-fluorodeoxy-D-glucose (FDG) PET scan can complement an augmented CT scan and help to identify radiologically-occult metastatic

disease⁴⁻⁶.

Optional Investigations:

- In the absence of metastatic disease (based upon the above investigations), the following tests may be of additional value if it would influence treatment decisions:
 - Bronchoscopy if tumor is located at or above the level of the carina.
 - Endoscopic ultrasound (establishes the depth of penetration into the esophageal wall, invasion into adjacent structures, and involvement of regional and non-regional lymph nodes) for clinically node negative, T1 or T2 tumors.
 - Pulmonary function testing (required prior to surgical resection and may be necessary prior to chemoradiotherapy).
- Bone scans can be done for patients suspected of having bone metastases, CT head or MRI for patients suspected of having brain metastases

Stage Information

Tumors involving the esophagogastric junction (EGJ) with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal rather than gastric cancers. In contrast, EGJ tumors with their epicenter located more than 2 cm into the proximal stomach are staged as stomach cancers (refer to gastric cancer guideline).

Table 1. AJCC Staging System for Esophageal Cancer, Eighth Edition⁷.

Definitions										
Depth of Tumour Penetration (T Stage): T ₀ No evidence of primary tumor T _{is} Carcinoma <i>in situ</i> or high-grade dysplasia T ₁ Tumor invades the lamina propria, muscularis mucosae, or submucosa T _{1a} Tumor invades the lamina propria or muscularis mucosae T _{1b} Tumor invades the submucosa T ₂ Invasion into muscularis propria T ₃ Invasion into adventitia T ₄ Tumor invades adjacent structures T _{4a} Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum T _{4b} Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway Regional* Lymph Node Involvement (N Stage): N ₀ No regional lymph node involvement N ₁ Involvement of one or two regional lymph nodes N ₂ Involvement of three to six regional lymph nodes N ₃ Involvement of seven or more regional lymph nodes						Distant Metastasis (M Stage): M ₀ No distant metastasis M ₁ Distant metastasis Histologic Grade (G Stage): G ₁ Well differentiated G ₂ Moderately differentiated G ₃ Poorly differentiated, undifferentiated Location of Squamous Cell Carcinomas: U Upper esophagus (20 to 25 cm from incisors) M Middle esophagus (>25 to 30 cm from incisors) L Lower esophagus (>30 to 40 cm from incisors) EGJ <i>Use this staging system if the tumour arises from the esophagogastric junction or from the stomach within 5 cm from esophagogastric junction and crosses the esophagogastric junction. Use the staging system for gastric cancer for all other tumours (epicenter in stomach more than 5 cm from the esophagogastric junction and without extension into esophagus).</i>				
Squamous Cell Carcinoma (Clinical)						Adenocarcinoma (Clinical)				
Stage	T	N	M	G	L	Stage	T	N	M	G
Stage 0	is	0	0	NA	NA	Stage 0	is	0	0	NA
Stage I	1	0-1	0	NA	NA	Stage I	1	0	0	NA
Stage II	2	0-1	0	NA	NA	Stage II _A	1	1	0	NA

	3	0	0	NA	NA	Stage II _B	2	0	0	NA
Stage III	3	1	0	NA	NA	Stage III	2	1	0	NA
	1-3	2	0	NA	NA		3	0-1	0	NA
Stage IV _A	4	0-2	0	NA	NA		4a	0-1	0	NA
Stage IV _B	Any	3	0	NA	NA	Stage IV _A	1-4a	2	0	NA
Stage IV _C	Any	Any	1	NA	NA		4b	0-2	0	NA
							Any	3	0	NA
						Stage IV _B	Any	Any	1	NA
Squamous Cell Carcinoma (Pathological)						Adenocarcinoma (Pathological)				
Stage	T	N	M	G	L	Stage	T	N	M	G
Stage 0	0	0	0	NA	Any	Stage 0	is	0	0	NA
Stage I _A	0	0	1	1	Any	Stage I _A	1a	0	0	1
	1a	0	0	X	Any		1a	0	0	X
Stage I _B	1a	0	0	2-3	Any	Stage I _B	1a	0	0	2
	1b	0	0	1-3	Any		1b	0	0	1-2
	1b	0	0	X	Any		1b	0	0	X
	2	0	0	1	Any	Stage I _C	1	0	0	3
Stage II _A	2	0	0	2-3	Any		2	0	0	1-2
	2	0	0	X	Any	Stage II _A	2	0	0	3
	3	0	0	Any	L		2	0	0	X
	3	0	0	1	U/M	Stage II _B	1	1	0	Any
Stage II _B	3	0	0	2-3	U/M		3	0	0	Any
	3	0	0	X	Any	Stage III _A	1	2	0	Any
	3	0	0	Any	X		2	1	0	Any
	1	1	0	Any	Any	Stage III _B	2	2	0	Any
Stage III _A	1	2	0	Any	Any		3	1-2	0	Any
	2	1	0	Any	Any		4a	0-1	0	Any
Stage III _B	2	2	0	Any	Any	Stage IV _A	4a	2	0	Any
	2	1-2	0	Any	Any	Stage IV _A	4b	0-2	0	Any
	4a	0-1	0	Any	Any	Stage IV _A	Any	3	0	Any
Stage IV _A	4a	2	0	Any	Any	Stage IV _B	Any	Any	1	Any
	4b	0-2	0	Any	Any					
	Any	3	0	Any	Any					
Stage IV _B	Any	Any	1	Any	Any					

Goals of Therapy

To render the patient free of disease, to relieve symptoms (e.g.: dysphagia), and to improve or prolong survival, if possible.

Recommendations¹⁴:

- Complete the work-up (as described above).
- For patients who do not have metastatic disease:
 - Early referral to a surgeon trained in esophageal surgery is important to assess for resectability.
 - Patients should be referred for a multidisciplinary discussion including radiation oncologists and medical oncologists prior to surgery for patients with resectable disease.
- Assess the degree of dysphagia and consult with a dietician to optimize the patient's nutritional


status. Consider placement of a nasogastric (NG) feeding tube. If the NG feeding tube insertion is technically difficult, placement should be performed radiographically.

- In a curative situation, avoid placement of an endoluminal stent as it increases the complication and mortality rate with radical chemoradiotherapy⁸.
- Patients who receive preoperative chemoRT should have a CT scan prior to surgery. In certain cases, FDG-PET can provide an assessment of response but should only be done if clinically warranted⁷⁻¹².
- Patients who receive perioperative FLOT should have a CT scan prior to surgery.
- There is limited data to support the use of imaging after definitive chemoRT or after surgical resection for non-metastatic patients, however, individualized discussion regarding imaging after definitive chemoRT or after surgical resection for non-metastatic patients may be appropriate in select clinical cases.
- For patients on palliative systemic treatment, CT chest, abdomen, and pelvis should be done every 2-3 months depending on the clinical situation.
- Consider treatment on a clinical trial, if available.

Table 2. Modified dysphagia score.

Modified Dysphagia Score ⁹	
0	Ability to eat normal diet
1	Ability to eat some solid food
2	Ability to eat semisolids only
3	Ability to swallow liquids only
4	Complete dysphagia

Figure 1: Operable esophagogastric cancer clinical stage II-III¹⁰⁻¹⁴.



* Multidisciplinary discussion recommended. For patients who get CROSS and have residual disease, consider adjuvant nivolumab. For gastric cancers, refer to the [Gastric Cancer Guidelines](#). For more details, refer to table 2.

Note: EGJ was redefined in the AJCC 8th edition: adenocarcinomas with epicenters no more than 2cm into the gastric cardia are staged as esophageal adenocarcinomas, and those extending further are staged as stomach cancers¹⁵.

Table 3. Curative therapy recommendations for patients with esophageal cancer.

Stage	Recommendations
T _{is} N ₀ or T _{1a} N ₀ Disease	Preferred Endoscopic Therapy for Superficial Cancers: - Endoscopic mucosal resection (EMR)¹⁶, submucosal dissection (ESD) and various ablation techniques (e.g.: photo-dynamic therapy¹⁷, argon plasma coagulation, radiofrequency ablation¹⁸, cryotherapy) can preserve the integrity of the esophagus and provide a potentially curative option for superficial cancers. - Provided careful endoscopic surveillance can be performed, consider for patients with favorable mucosal tumours* who are interested in an esophagus-sparing approach or who are elderly, with multiple comorbidities, or otherwise high surgical risk. *Note: Favorable mucosal tumours include non-invasive (<i>in situ</i>) lesions or disease that invades into the mucosa (but <i>not</i> submucosa).

			Stage	Description	Chance of Lymph Node Involvement
			T _{is} (m1)	Presence in the epithelial layer of the mucosa	0%
			T _{1a} (m2)	Invasion into lamina propria mucosal	0%
			T _{1a} (m3)	Invasion into (not through) muscularis mucosae	7%
			T _{1b} (sm1)	Invasion into superficial third of submucosa	15%
			T _{1b} (sm2)	Invasion into middle third of submucosa	27%
			T _{1b} (sm3)	Invasion into deepest third of submucosa	49%
T _{1b} N ₀ Disease	Alternate	Esophagectomy: - Resect disease if both technically and medically feasible. Aim to achieve an “R₀” resection (no gross or microscopic residual tumour). - Post-operative morbidity and survival are significantly better when surgery is completed in an experienced centre¹⁹.			
	Preferred	Esophagectomy: Esophagectomy is the preferred treatment choice for fit patients with superficial esophageal cancers invading the submucosa.			
	Alternate	Endoscopic therapy: - For most patients with favorable intramucosal tumors, who are interested in an esophagus-sparing approach or are older with multiple comorbidities or are otherwise high surgical risk are candidates for endoscopic resection rather than surgical resection. - If a patient is not medically operable, declines surgery, or is not a candidate for EMR/ESD, refer to Table 3			
Squamous cell cancer T ₂ , T ₃ , N ₊ , M ₀ Disease*	Preferred	Pre-Operative Chemoradiotherapy followed by Esophagectomy (if possible): - CROSS pre-operative chemoradiation (Level 1 evidence): Deliver 4,140 cGy in twenty-three fractions over five weeks plus Paclitaxel 50 mg/m² IV and Carboplatin AUC 2 IV on days 1, 8, 15, 22, and 29¹⁰. This protocol improves the R₀ resection rate (92% <i>versus</i> 69%) and overall survival (HR 0.657, CI_{95%} 0.495-0.871, <i>p</i> = 0.003) when compared to surgery alone. It prolongs median survival from 24.0 months to 49.4 months and increases the one-, two-, three-, and five-year survival rates from 70% to 82%, 50% to 67%, 44% to 58%, and 34% to 47% respectively. It offers a pCR rate of 23%. 75% of the patients enrolled had adenocarcinoma. About 25% of patients had disease at the esophagogastric junction. - Aim to achieve an “R₀” resection (no gross or microscopic residual tumour). - Post-operative morbidity and survival are significantly better when surgery is completed in an experienced centre¹⁹. •Post-operative Adjuvant Therapy: The Checkmate 577 trial randomized patients who received preoperative CROSS chemoradiotherapy followed by surgery with residual pathological disease (> ypT1 and/or >ypN1) to nivolumab (240 mg/m ² IV q 2 weekly for up to 1 year) or placebo. Disease free survival (DFS) was significantly improved in the nivolumab group compared to the placebo (median 22.4 months versus 11.0 months, HR 0.69, 95% CI			

*Note that esophagectomy alone is an option in low risk cT2N0 patients.

		0.56-0.86, $p=0.003$)²⁰. • No randomized trial (and at least two meta-analyses^{21,22} has demonstrated a survival advantage for preoperative chemoradiotherapy over chemotherapy alone • One network meta-analysis concluded that there is a survival benefit for neoadjuvant chemoradiotherapy over neoadjuvant chemotherapy²³. ○ 31 randomized controlled trials involving 5496 patients were included in the quantitative analysis ○ Neoadjuvant chemoradiotherapy improved overall survival when compared to all other treatments including: ○ Surgery alone (HR 0.75, 95% CI 0.67-0.85) ○ Neoadjuvant chemotherapy (HR 0.83, 95% CI 0.70-0.96) and ○ Neoadjuvant radiotherapy (HR 0.82, 95% CI 0.67-0.99) • In the neoadjuvant setting, treatment with chemoradiotherapy yields higher rates of pCRs and R0 resections compared to chemotherapy. Chemoradiation is also of shorter duration and there is no need for a central line. Decisions regarding the optimal neoadjuvant therapeutic modality warrants a multidisciplinary discussion incorporating the planned surgery, tumor anatomy, patient wishes and comorbidities.
Adenocarcinoma cT2-T4 or cN+ M ₀ Disease	Chemotherapy	Peri-Operative Chemotherapy: FLOT : (fluorouracil, leucovorin, oxaliplatin, docetaxel, (Level 1 evidence) ESOPEC demonstrated the superiority of perioperative FLOT compared to preoperative chemoradiation with carboplatin and paclitaxel (CROSS) in patients with adenocarcinoma of the esophagus and GE junction²⁴. Median survival with FLOT was 66 months versus 37 months (HR 0.70; 95% CI, 0.53 to 0.92; $P=0.01$). In the FLOT4-AIO trial, FLOT was superior to epirubicin, cisplatin and fluorouracil /capecitabine for resectable cT2 or cN1+ gastric and gastroesophageal adenocarcinomas. Patients with Siewart type 1 to 3 gastroesophageal adenocarcinoma comprised 56% of patients in the trial. Median survival with FLOT was 50 months versus 35 months with ECF/ECX HR 0.77(, CI_{95%} 0.63-0.94, $p=0.012$)¹⁸. • Perioperative chemotherapy with FLOT consists of 4 cycles of chemotherapy prior to surgery with a further 4 cycles of chemotherapy post-surgery. Each cycle lasts 14 days and consists of 5-FU 2600 mg/m² (24 h) day 1 and leucovorin 200 mg/m² (2h), day 1 and oxaliplatin 85 mg/m² (2 h) day 1 and docetaxel 50 mg/m² (1 h), every 2 weeks. Prophylactic GCSF should be considered for patients undergoing FLOT, as grade 3/4 neutropenia occurs at a higher rate than ECF/ECX. • Maximum benefit with N+ or T3-4 or age <60 years²⁴. Alternatives for patients not candidates for FLOT CROSS: pre-operative chemoradiation followed by adjuvant Nivolumab if residual disease^{10,20}. • MAGIC: When compared to surgery alone in patients with good performance status (ECOG ≤1) and T₂₋₄N₀₋₃M₀ adenocarcinoma of the distal third of the esophagus, gastro-esophageal junction, or stomach, peri-operative chemotherapy improves the

five-year progression-free (HR 0.66, CI_{95%} 0.53-0.81, $p < 0.001$) and overall survival (from 23.0% to 36.3%, HR 0.74, CI_{95%} 0.59-0.93, $p = 0.008$ ¹⁹).

- *Pre-Operative Phase:* Three three-week cycles of Epirubicin 50 mg/m² and Cisplatin 60 mg/m² IV on day one plus a continuous intravenous infusion of 5-Fluorouracil 200 mg/m²/day over twenty-one days.
- *Operative Phase:* Perform surgical resection with oncologic principles.
- *Post-Operative Phase:* As described in the pre-operative phase (above).

Alternative for patients not candidates for epirubicin (MAGIC): cisplatin 5FU has been evaluated in patients with operable adenocarcinoma of the esophagus and gastroesophageal junction

- The FFCD trial six peri-operative cycles of Cisplatin and infusional fluorouracil improves the five-year disease-free survival (34% *versus* 19%, HR 0.65, CI_{95%} 0.48-0.89, $p = 0.003$), overall survival (38% *versus* 24%, HR 0.69, CI_{95%} 0.50-0.95, $p = 0.02$), and rate of curative resection (84% *versus* 73%, $p = 0.04$) compared to surgery alone. Chemotherapy was given every 4 weeks and was comprised of cisplatin 100 mg/m² IV on day one plus 5-Fluorouracil 800 mg/m²/day over days one through five days, every 28 days²⁵.
- The OE5 trial randomized patients to 4 cycles of ECX or 2 cycles of cisplatin and infusional fluorouracil prior to surgery. The pathological complete response rate was higher in the ECX arm compared to cisplatin/fluoruracil (11% vs 3%). However, there was no significant difference in overall survival (23.4 months vs 26.1 months, HR 0.90 0.77-1.05, $p = 0.19$)¹⁴
- These regimens require placement of a central venous catheter (CVC), peripherally inserted central catheter (PICC line), or port.
- For patients in whom it is not possible to resect disease due to medical or technical issues, refer to Table 3

Table 3. Recommendations for patients with esophageal cancer who are not candidates for surgery.

Stage	Recommendations	
T ₁₋₄ N ₀₋₃	Preferred Recommendation	In whom it is not possible to resect disease due to medical or technical issues: Primary ('Definitive') Chemoradiotherapy: - The two treatment options are: Preferred: Deliver 5,000 cGy in twenty-five fractions over five weeks plus Oxaliplatin 85 mg/m² IV and Leucovorin 200 mg/m² IV followed by 5-Fluorouracil 400 mg/m² IV bolus followed by 5-Fluorouracil 800 mg/m²/day over days one and two on weeks one, three, five, seven, nine, and eleven. This regimen is associated with less mucositis, alopecia, and renal toxicity plus numerically fewer toxic and sudden deaths but without a difference in overall survival, progression-free survival, and pCR rate²⁶. (Level 1 evidence) Alternatively deliver 5,000 cGy in twenty-five fractions over five weeks plus Cisplatin 75 mg/m² IV over one hour and 5-Fluorouracil 4,000 mg/m² IV over ninety-six hours on weeks one, five, eight, and eleven. This protocol offers an five-year overall survival rate of 27% (compared to 0% for radiotherapy alone)²⁷. Note: 82% of the patients enrolled had squamous cell carcinoma of the esophagus. - These regimens require placement of a central venous catheter (CVC), peripherally inserted central catheter (PICC line), or port.
	Alternate	Radiotherapy Alone: Consider for patients who decline chemotherapy or in whom chemotherapy is deemed unsafe.

Recommendations for Incurable Situations

Provide palliative maneuvers to maintain and/or improve quality of life:

1. Relieve pain, bleeding, and/or dysphagia with radiotherapy (30 Gy in 10 fractions is preferred, alternatively 40 Gy in 15 fractions or 50 Gy in 20 fractions).
2. Consider placement of an endoluminal stent^{28,29} or photodynamic therapy³⁰ to relieve dysphagia.
3. Patients with advanced esophageal cancer who have a self expanding metal stent inserted for the primary management of dysphagia do not gain additional benefit from concurrent palliative radiotherapy (Level 1 evidence). Palliative radiotherapy may be indicated for bleeding³¹.
4. Consider palliative chemotherapy to control disease and prolong survival in patients with a satisfactory performance status (ECOG ≤ 2)³²⁻³⁸.
5. Consider treatment on a clinical trial if available.
6. Consider early referral to palliative care. (Symptom management guidelines can be found [here](#)).
7. Refer to dieticians and consider psychosocial referral. Early interdisciplinary care with the addition of psychologists and dieticians improved survival compared to standard oncology care in phase III trial of untreated patients with metastatic upper GI cancers (median overall survival 14.8 months vs 11.9 months, HR 0.68; 95% CI 0.51-0.9; = 0.021).

Table 4. ECOG Performance Status Scale.

ECOG	Description of Performance Status
0	Fully active and able to carry on without restriction.
1	Unable to carry out physically strenuous activities but ambulatory and able to complete work of a light or sedentary nature.
2	Ambulatory and capable of all self-care but unable to complete work activities. Up and about more than 50% of waking hours.
3	Capable of only limited self-care and/or confined to a bed or chair for more than 50% of waking hours.
4	Completely disabled. Unable to carry out any self-care. Totally confined to a bed or chair.

Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Many phase III clinical trials for metastatic gastric cancer also included patients with adenocarcinoma of the gastroesophageal junction. By extrapolation, patients with metastatic adenocarcinoma of the esophagus and gastroesophageal junction are treated as per metastatic gastric cancers. [Link to [Gastric Guideline](#)].

Evaluation of HER2 protein expression via immunohistochemistry or in situ hybridization is recommended to select patients with metastatic esophageal/gastroesophageal adenocarcinoma for trastuzumab based treatment⁴².

Metastatic Squamous Cell Cancer of the Esophagus

The combination of a platinum with a fluoropyrimidine is the preferred first line regimen^{39,40}.

- **Pembrolizumab plus platinum-fluoropyrimidine based chemotherapy** if CPS high [I,A]. The KEYNOTE-590 trial randomized patients with advanced esophageal carcinoma (adenocarcinoma or squamous, N=749) to Pembrolizumab plus cisplatin/infusional 5FU chemotherapy versus chemotherapy alone. After a median follow-up of 10.8 months, Pembrolizumab + chemo demonstrated superior OS in ESCC patients (median OS 12.6 mo vs. 9.8 mo; HR: 0.72; 95%CI: 0.43-0.75; $p < 0.001$). The benefit was seen in all patients, but primarily driven by the patients with squamous cell cancer⁴¹. The magnitude of benefit is highest in patients with high CPS scores.
 - CPS ≥ 1 - HR: 0.69 (95%CI: 0.56-0.85) (FDA recommendation)
 - CPS ≥ 10 – HR: 0.57 (95%CI: 0.44-0.75) [I,A] (ESMO recommendation)
- For patients who are PD-L1 negative/low: **platinum-fluoropyrimidine based chemotherapy** is recommended [II,A]. Oxaliplatin based chemotherapy is a reasonable option. A phase II trial evaluated FOLFOX (100) in metastatic squamous cell cancer of the esophagus. The response rate was 23.2% with a median overall survival of 7.7 months⁴²
- Patients with squamous cell esophageal cancer comprised approximately 10% of patients in the REAL-2 trial. Capecitabine-based combination regimens (e.g.: ECX, EOX, CX) offer a superior response rate (45.6% *versus* 38.4%, OR 1.38, CI_{95%} 1.10-1.73, $p = 0.006$) and overall survival (HR 0.87, CI_{95%} 0.77-0.98, $p = 0.02$) when compared to 5-Fluorouracil-based combination chemotherapies (e.g.: ECF, EOF, CF).
- ECX offers a median survival of about ten months and a one-year survival of around 40%²⁹. It is administered in three- week cycles where Epirubicin (50 mg/m² IV over twenty minutes) and Cisplatin (60 mg/m² IV over one hour along with hydration) are administered on day one. Capecitabine (625 mg/m² PO Q12h) is administered for twenty-one consecutive days.
- If a patient is unable to tolerate oral medications but remains a candidate for palliative chemotherapy, consider ECF. It is administered in three-week cycles as for ECX but, instead of Capecitabine, 5-Fluorouracil (200 mg/m²/day) is administered as a continuous intravenous infusion through a central venous catheter (“CVC”) or a peripherally inserted central catheter (“PICC line”).
- In a separate analysis of the REAL-2 clinical trial, thromboembolic events occur in 11.4% of patients (9.4% are venous events and 2.0% are arterial events)⁴³. They undermine overall survival (7.4 months *versus* 10.5 months, HR 0.80, CI_{95%} 0.64-0.99, $p = 0.043$). When compared to Cisplatin, Oxaliplatin confers a lower risk for thromboembolic events. A meta-analysis confirmed that the use of Oxaliplatin reduced the risk of death (HR 0.88, CI_{95%} 0.78-0.99, $p = 0.04$), progression (HR 0.88, CI_{95%} 0.80-0.98, $p = 0.02$), and thromboembolism⁴⁴.

Second Line Therapy⁴⁵

The ATTRACTION-3 study randomized patients with advanced esophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy to nivolumab versus chemotherapy of physician's choice (paclitaxel 100 mg/m² q week for 6 weeks followed by 1 week off) or docetaxel (75 mg/m² q3 weeks). Overall survival was significantly improved in the nivolumab group compared to chemotherapy (median 10.9 months versus 8.4 months, HR 0.77, 95% CI 0.62-0.96; p=0.019). There was no significant difference in progression free survival for nivolumab versus chemotherapy (median 1.7 months versus 3.4 months, HR 1.08, 95% CI 0.87–1.34). The prespecified interaction analysis indicated no significant interaction of treatment effect by PD-L1 status. Nivolumab is not currently available on the Alberta CancerCare Drug Benefit List.

Chemotherapy with a taxane or irinotecan⁴⁶⁻⁴⁸ [II,B] would be a reasonable alternative option and are available through [the Alberta CancerCare Drug Benefit List](#).

References

1. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *New England Journal of Medicine*. 1999;340(11):825-831.
2. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *Cancer*. 1998;83(10):2049-2053.
3. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. *Seminars in oncology*. 1999;26(5 Suppl 15):2-8.
4. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. *Journal of Clinical Oncology*. 2004;22(18):3805-3812.
5. Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. *Journal of Thoracic & Cardiovascular Surgery*. 2007;133(3):738-745.
6. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. *Journal of Clinical Oncology*. 2000;18(18):3202-3210.
7. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. *Annals of surgical oncology*. 2010;17(7):1721-1724. doi:10.1245/s10434-010-1024-1 [doi]
8. Nishimura Y, Nagata K, Katano S, et al. Severe complications in advanced esophageal cancer treated with radiotherapy after intubation of esophageal stents: a questionnaire survey of the Japanese Society for Esophageal Diseases. *International journal of radiation oncology, biology, physics*. 2003;56(5):1327-1332.
9. Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. *New England Journal of Medicine*. 1993;329(18):1302-1307.
10. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *New England Journal of Medicine*. 2012;366(22):2074-2084. doi://dx.doi.org/10.1056/NEJMoa1112088
11. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet (London, England)*. 2019;393(10184):1948-1957. doi:S0140-6736(18)32557-1 [pii]
12. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *New England Journal of Medicine*. 2006;355(1):11-20.
13. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *Journal of Clinical Oncology*. 2011;29(13):1715-1721. doi://dx.doi.org/10.1200/JCO.2010.33.0597
14. Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. *The Lancet Oncology*. 2017;18(9):1249-1260. doi:10.1016/S1470-2045(17)30447-3; 24
- 10.1016/S1470-2045(17)30447-3
15. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. *Ann Cardiothorac Surg*. Mar 2017;6(2):119-130. doi:10.21037/acs.2017.03.14
16. Ciocirlan M, Lapalus MG, Hervieu V, et al. Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus. *Endoscopy*. 2007;39(1):24-29.
17. Seewald S, Ang TL, Groth S, et al. Detection and endoscopic therapy of early esophageal adenocarcinoma. *Current opinion in gastroenterology*. 2008;24(4):521-529. doi://dx.doi.org/10.1097/MOG.0b013e3282ff8b1f
18. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. *New England Journal of Medicine*. 2009;360(22):2277-2288. doi://dx.doi.org/10.1056/NEJMoa0808145
19. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. *New England Journal of Medicine*. 2002;346(15):1128-1137.
20. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med*. Apr 1 2021;384(13):1191-1203. doi:10.1056/NEJMoa2032125
21. Pasquali S, Yim G, Vohra RS, et al. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. *Annals of Surgery*. 2017;265(3):481-491. doi:10.1097/SLA.0000000000001905 [doi]

22. Deng HY, Wang WP, Wang YC, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery*. 2017;51(3):421-431. doi:10.1093/ejcts/ezw315 [doi]
23. Chan KKW, Saluja R, Delos Santos K, et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis. *International journal of cancer*. 2018;143(2):430-437. doi:10.1002/ijc.31312 [doi]
24. Hoepfner J, Brunner T, Schmoor C, et al. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. *N Engl J Med*. Jan 23 2025;392(4):323-335. doi:10.1056/NEJMoa2409408
25. Mariette C, Seitz J, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. *J Clin Oncol 2010 ASCO Annual Meeting Proceedings*. 2010;28(15S):4005.
26. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *The Lancet Oncology*. 2014;15(3):305-314. doi:10.1016/S1470-2045(14)70028-2 [doi]
27. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA*. 1999;281(17):1623-1627.
28. Saxon RR, Morrison KE, Lakin PC, et al. Malignant esophageal obstruction and esophagorespiratory fistula: palliation with a polyethylene-covered Z-stent. *Radiology*. 1997;202(2):349-354.
29. Baron TH. Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. *New England Journal of Medicine*. 2001;344(22):1681-1687.
30. Little VR, Luketich JD, Christie NA, et al. Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients. *Annals of Thoracic Surgery*. 2003;76(5):1687-1692.
31. Adamson D, Byrne A, Porter C, et al. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet Gastroenterol Hepatol*. Apr 2021;6(4):292-303. doi:10.1016/s2468-1253(21)00004-2
32. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. *Seminars in oncology*. 1999;26(5 Suppl 15):12-20.
33. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *New England Journal of Medicine*. 2008;358(1):36-46. doi://dx.doi.org/10.1056/NEJMoa073149
34. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced esophago-gastric cancer. *Annals of Oncology*. 2009;20(9):1529-1534. doi://dx.doi.org/10.1093/annonc/mdp047
35. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *Journal of Clinical Oncology*. 2002;20(8):1996-2004.
36. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. *Journal of Clinical Oncology*. 1997;15(1):261-267.
37. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. *British journal of cancer*. 1999;80(1-2):269-272.
38. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *Journal of Clinical Oncology*. 2006;24(18):2903-2909.
39. Muro K, Lordick F, Tsushima T, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2019;30(1):34-43. doi:10.1093/annonc/mdy498 [doi]
40. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D, Committee EG. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2016;27(suppl 5):v50-v57. doi:mdw329 [pii]
41. Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. *Lancet*. Aug 28 2021;398(10302):759-771. doi:10.1016/s0140-6736(21)01234-4

42. Wang J, Chang J, Yu H, et al. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. *Cancer chemotherapy and pharmacology*. 2013;71(4):905-911. doi:10.1007/s00280-013-2081-5 [doi]
43. Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. *Journal of Clinical Oncology*. 2009;27(23):3786-3793. doi://dx.doi.org/10.1200/JCO.2008.19.4274
44. Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. *Gastric Cancer*. 2011;14(1):50-55. doi://dx.doi.org/10.1007/s10120-011-0007-7
45. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. Nov 2019;20(11):1506-1517. doi:10.1016/s1470-2045(19)30626-6
46. Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. *Cancer Chemother Pharmacol*. Jun 2011;67(6):1265-72. doi:10.1007/s00280-010-1422-x
47. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. *Ann Oncol*. Jun 2004;15(6):955-9. doi:10.1093/annonc/mdh231
48. Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. *Anticancer Res*. Jul-Aug 2007;27(4c):2845-8.

Development and Revision History

This guideline was developed by a multidisciplinary working group comprised of members from the Alberta Provincial GI Tumour Team, external participants identified by the Working Group Lead, and a methodologist from the Guideline Resource Unit. The draft guideline was externally reviewed and endorsed by members of the Alberta Provincial GI Tumour Team who were not involved in the guideline's development, including surgical oncologists, radiation oncologists, medical oncologists, gastroenterologist, nurses, pathologists, and pharmacists. A detailed description of the methodology followed during the guideline development process can be found in the [Guideline Resource Unit Handbook](#).

This guideline was originally developed in 2010.

Levels of Evidence

I	Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomized trials without heterogeneity
II	Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity
III	Prospective cohort studies
IV	Retrospective cohort studies or case-control studies
V	Studies without control group, case reports, expert opinion

Strength of Recommendations

A	Strong evidence for efficacy with a substantial clinical benefit; strongly recommended
B	Strong or moderate evidence for efficacy but with a limited clinical benefit; generally recommended
C	Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.); optional
D	Moderate evidence against efficacy or for adverse outcome; generally not recommended
E	Strong evidence against efficacy or for adverse outcome; never recommended

Maintenance

A formal review of the guideline will be conducted in 2026. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

Abbreviations

AJCC, American Joint Committee on Cancer; CF, cisplatin + 5-fluorouracil; CI, confidence interval; CT, computed tomography; CVC, central venous catheter; CX, cisplatin + Capecitabine; ECF, epirubicin + cisplatin + 5-fluorouracil; ECOG, Eastern Cooperative Oncology Group; ECX, epirubicin + cisplatin + Capecitabine; EMR, endoscopic mucosal resection; EOF, epirubicin + oxaliplatin + 5-fluorouracil; EOX, epirubicin + oxaliplatin + Capecitabine; FDG-PET, fluorodeoxy-D-glucose positron emission tomography; HR, hazard ratio; IV, intravenous; NG, nasogastric; OR, odds ratio; pCR,

pathological complete response; PICC, peripherally inserted central catheter; TNM, tumour-node-metastasis.

Disclaimer

The recommendations contained in this guideline are a consensus of the Alberta Provincial GI Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.

Copyright © (2025) Alberta Health Services

This copyright work is licensed under the [Creative Commons Attribution-NonCommercial-NoDerivative 4.0 International license](#). You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, do not adapt the work, and abide by the other license terms. To view a copy of this license, see <https://creativecommons.org/licenses/by-nc-nd/4.0/>. The license does not apply to AHS trademarks, logos or content for which Alberta Health Services is not the copyright owner.

Funding Source

Financial support for the development of Cancer Care Alberta's evidence-based clinical practice guidelines and supporting materials comes from the Cancer Care Alberta operating budget; no outside commercial funding was received to support the development of this document.

All cancer drugs described in the guidelines are funded in accordance with the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents of Alberta, unless otherwise explicitly stated. For a complete list of funded drugs, specific indications, and approved prescribers, please refer to the [Outpatient Cancer Drug Benefit Program Master List](#).

Conflict of Interest Statements

Dr. Rachid Mohamed has nothing to disclose.

Dr. Diane Severin has nothing to disclose.

Dr. Colin Schieman has nothing to disclose.

Dr. Patricia Tang reports personal fees from Celgene, Genomic Health International, Amgen, Merck, Taiho Pharmaceutical, AstraZeneca, Pfizer, and Novartis.

Derek Tilley has nothing to disclose.

Dr. Clarence Wong reports grants from Alberta Innovates, personal fees from Allergan, personal fees from Medtronic, personal fees from Takeda, personal fees from Pendopharm, grants from Somagen, outside the submitted work.

Citation

Mohamed R, Severin D, Schieman C, Tang P (Lead), Tilley D, Wong C. Cancer Care Alberta, Alberta Health Services (2025). Clinical Practice Guideline on Esophageal Cancer v7. Accessed [Month, Year]. Available from: www.ahs.ca/guru